UB Paderborn / Katalog / Suche / in CDI

Characterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters

PloS one, 2018-09, Vol.13 (9), p.e0202749

2018

Volltextzugriff (PDF)

Targeting vascular endothelial growth factor receptor 2 and protein kinase D1 related pathways by a multiple kinase inhibitor in angiogenesis and inflammation related processes in vitro

PloS one, 2015-04, Vol.10 (4), p.e0124234-e0124234

2015

Volltextzugriff (PDF)

Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases

European journal of medicinal chemistry, 2019-12, Vol.184, p.111710-111710, Article 111710

2019

Volltextzugriff (PDF)

Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors

ACS medicinal chemistry letters, 2014-04, Vol.5 (4), p.298-303

2014

Volltextzugriff (PDF)

Protein kinase inhibitor as a potential candidate for epilepsy treatment

Epilepsia (Copenhagen), 2011-03, Vol.52 (3), p.579-588

2011

Volltextzugriff (PDF)

Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma

Bioorganic & medicinal chemistry letters, 2018-02, Vol.28 (4), p.769-773

2018

Volltextzugriff (PDF)

Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells

European journal of medicinal chemistry, 2016-01, Vol.108, p.623-643

2016

Volltextzugriff (PDF)

Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML

Bioorganic & medicinal chemistry letters, 2018-08, Vol.28 (14), p.2391-2398

2018

Volltextzugriff (PDF)

Discovery and optimization of novel benzothiophene-3-carboxamides as highly potent inhibitors of Aurora kinases A and B

Bioorganic & medicinal chemistry letters, 2018-10, Vol.28 (19), p.3265-3270

2018

Volltextzugriff (PDF)

Leads for antitubercular compounds from kinase inhibitor library screens

Tuberculosis (Edinburgh, Scotland), 2010-11, Vol.90 (6), p.354-360

2010

Volltextzugriff (PDF)

Development of a 3D Tissue Culture–Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases

Journal of biomolecular screening, 2016-10, Vol.21 (9), p.912-922

2016

Volltextzugriff (PDF)

Lead selection and characterization of antitubercular compounds using the Nested Chemical Library

Tuberculosis (Edinburgh, Scotland), 2015-06, Vol.95, p.S200-S206

2015

Volltextzugriff (PDF)

Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes

Bioorganic & medicinal chemistry letters, 2016-01, Vol.26 (2), p.424-428

2016

Volltextzugriff (PDF)

Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods

Mini reviews in medicinal chemistry, 2004-02, Vol.4 (2), p.167

2004

Volltextzugriff (PDF)

Correction: Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro

PloS one, 2015-12, Vol.10 (12), p.e0144792-e0144792

2015

Volltextzugriff (PDF)

NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling

Arteriosclerosis, thrombosis, and vascular biology, 2014-08, Vol.34 (8), p.1704

2014

Volltextzugriff (PDF)

Validation subset selections for extrapolation oriented QSPAR models

Molecular diversity, 2003, Vol.7 (1), p.37-43

2003

Volltextzugriff (PDF)

Targeted drug combination therapy design based on driver genes

Oncotarget, 2019-09, Vol.10 (51), p.5255-5266

2019

Volltextzugriff (PDF)

Protein kinase inhibitor as a potential candidate for epilepsy treatment: Kinase Inhibitor against Epilepsy

Epilepsia (Copenhagen), 2011-03, Vol.52 (3), p.579-588

2011

Volltextzugriff (PDF)

Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology

Assay and drug development technologies, 2005-10, Vol.3 (5), p.543-551

2005

Volltextzugriff (PDF)

Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR

Current opinion in molecular therapeutics, 2009-06, Vol.11 (3), p.308

2009

Volltextzugriff (PDF)

Development and study of structure-activity relationship of drugs against Mycobacterium tuberculosis

Acta pharmaceutica Hungarica, 2013, Vol.83 (3), p.88-95

2013

Volltextzugriff (PDF)

Developing FGFR inhibitors as potential anti-cancer agents

Acta pharmaceutica Hungarica, 2013, Vol.83 (2), p.47-56

2013

Volltextzugriff (PDF)

Development and biochemical characterization of EGFR/c-Met dual inhibitors

Acta pharmaceutica Hungarica, 2013, Vol.83 (4), p.121-133

2013

Volltextzugriff (PDF)

Development of PAK1 kinase inhibitors with "in silico" modeling methods

Acta pharmaceutica Hungarica, 2010, Vol.80 (4), p.155-161

2010

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Characterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters

Targeting vascular endothelial growth factor receptor 2 and protein kinase D1 related pathways by a multiple kinase inhibitor in angiogenesis and inflammation related processes in vitro

Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases

Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors

Protein kinase inhibitor as a potential candidate for epilepsy treatment

Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma

Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells

Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML

Discovery and optimization of novel benzothiophene-3-carboxamides as highly potent inhibitors of Aurora kinases A and B

Leads for antitubercular compounds from kinase inhibitor library screens

Development of a 3D Tissue Culture–Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases

Lead selection and characterization of antitubercular compounds using the Nested Chemical Library

Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes

Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods

Correction: Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro

NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling

Validation subset selections for extrapolation oriented QSPAR models

Targeted drug combination therapy design based on driver genes

Protein kinase inhibitor as a potential candidate for epilepsy treatment: Kinase Inhibitor against Epilepsy

Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology

Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR

Development and study of structure-activity relationship of drugs against Mycobacterium tuberculosis

Developing FGFR inhibitors as potential anti-cancer agents

Development and biochemical characterization of EGFR/c-Met dual inhibitors

Development of PAK1 kinase inhibitors with "in silico" modeling methods

Suchergebnisse filtern